In 242 Chinese adults with overweight or obesity (locally defined BMI thresholds), weekly semaglutide 2·4 mg plus lifestyle intervention reduced bodyweight by 12·1% vs 2·2% with placebo at 44 weeks; 80·5% vs 24·4% lost ≥5%. Adverse events: 87·6% vs 75·3%, mainly gastrointestinal.
RCTn = 242
Guo et al. Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial